A 67-Year-Old-Man with Metastatic Prostate Cancer - Episode 4

The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

EP. 1: Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer
EP. 2: Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
EP. 3: Factors for Consideration When Selecting Treatments for Patients with mCRPC
Now Viewing
EP. 4: The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
EP. 5: Unmet Needs, Future Directions, and Clinical Pearls in mCRPC